Vertex has initial success in new diabetes project

Remarkably positive insulin results have arrived from Vertex's first patient in the phase I/II trial of its stem cell therapy against type 1 diabetes.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

Published: 19.10.21 at 14:42

The results from the first patient to receive Vertex's treatment for type 1 diabetes, VX-880, a therapy derived from stem cells, have been a cause for celebration for the Boston-based biotech company, it reports in a press release.

The patient's need for daily insulin doses has drastically decreased after they were injected with Vertex's synthetic insulin-producing cell therapy in combination with an immunosuppressive therapy.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.